Login / Signup

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data.

Vivian P BykerkPeter NashDavid NichollsYoshiya TanakaKevin WinthropChristina PopovaNicola TiltDerek Haaland
Published in: Rheumatology and therapy (2023)
CZP durability was comparable with durability data on other bDMARDs in RA patients. Patient characteristics that were associated with greater durability included younger age, TNFi-naïvety, and disease duration ≥ 1 year. Findings may be helpful in informing clinicians on a patient's likelihood of discontinuing CZP, based on their baseline characteristics.
Keyphrases